BOZEN, Sud-Tirol, Italy: Health Robotics
today announced that its joint venture Health Robotics South East Asia Ltd.
scored two strategic wins by reaching agreements on two separate
government-sponsored projects to deliver CytoCare-made accurate and sterile
oncology patient doses in Kuala Lumpur and Bangkok, respectively. Health
Robotics' CytoCare is the first and only robot in the world proven to
automatically compound and dispense oncology intravenous therapy treatments
to patients.
Health Robotics South East Asia announced the opening of two outsourcing
centers within close distance to Kuala Lumpur General Hospital in 4Q2010 and
the National Cancer Institute Thailand in 1Q 2011, respectively. These two
key projects consolidate the leadership position of Health Robotics SEA
within Private Finance Initiatives (PFIs) in the region [PFIs are initiatives
that, in addition to products and services, provide financial support under
public-private partnerships]. The contracted plan for the outsourcing centers
already includes the purchase of CytoCare and i.v.STATION robotic devices,
and a state-of-the-art logistics system already in place for other medical
supplies. These assets will be complemented by Health Robotics SEA's future
selection of strategic partners for compounding services, IV consumables, and
both generic and proprietary oncology medications to be used in the 2
centers, all currently in the process of vendor selection.
"I'm very pleased that our South East Asia joint venture's chemotherapy
outsourcing and PFI strategies are beginning to produce outstanding results.
I look forward to their future expansion to all government-owned hospitals in
Malaysia and Thailand, as well as quick geographical expansion into other
countries in the region, such as Singapore, India and Vietnam. We are firm
believers that the 'pay-per-dose' outsourcing business model is an excellent
fit for our best-in-class technology and workflow processes in the region,
offering a win-win scenario to capital-starved public hospitals. I have
personally witnessed in Turkey the excellent results of a similar
'pay-per-dose' outsourcing model in combination with a government-sponsored
partnership, resulting in orders for 24 CytoCare robots within the past 2
years from our Turkish strategic partner Rivosem. We plan similar
'pay-per-dose' outsourcing business models wherever applicable, including
selected countries in Western Europe," stated Werner Rainer, Health Robotics'
CEO.
About Health Robotics:
Health Robotics is the undisputed global leading supplier of
life-critical intra-venous medication robots, providing healthcare facilities
in 5 continents with robotics technology and software automation solutions
deployed utilizing virtual high-availability technology. Its world-leading
solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs],
i.v.SOFT(TM) [workflow engine for manual compounding, powered by
MEDarchiver], and TPNstation(TM) [totally-automated parenteral nutrition]
have and will greatly contribute to ease hospitals' growing pressures to
improve patient safety, increase throughput and contain costs. Through the
effective and efficient production of sterile, accurate, tamper-evident and
ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate
life-threatening drug-exchange errors, decrease other therapy oversights and
sterility risks, work more efficiently, reduce waste and controlled
substances' diversion, and diminish the gap between rising patient
volume/acuity and scarce nursing and pharmacy staff.
